Skip to main content

Table 1 Patient characteristics at baseline (n = 24)

From: Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

  all patients (n = 24) previous mepolizumab treatment (−) (n = 13) previous mepolizumab treatment (+) (n = 11) p value between two groups
male, n (%) 9 (38) 4 (31) 5 (45) 0.68
age (years), mean (SD) (range) 57.5 (13.4) (20–75) 56.7 (15.8) (20–75) 58.4 (10.6) (38–72) 0.91
disease duration, (years), mean (SD) (range) 21.3 (12.5) (4–54) 21.2 (14.2) (4–54) 21.5 (10.7) (8–36) 0.68
body mass index (kg/m2), mean (SD) 23.4 (4.8) 24.6 (5.1) 21.9 (4.1) 0.19
smoking (never/former), n 18 / 6 9 / 4 9 / 2 0.65
initial treatments use
 —ICS/LABA, n (%) 24 (100) 13 (100) 11 (100)
 —ICS dose (μg), mean (SD), budesonide equivalent 1381 (448) 1411 (518) 1345 (370) 0.66
 —LAMA, n (%) 14 (58) 7 (54) 7 (64) 0.70
 —LTRA, n (%) 20 (83) 11 (85) 9 (82) > 0.99
 —xanthine derivative, n (%) 17 (71) 9 (69) 8 (73) > 0.99
 —maintenance therapy of OCS, n (%) 8 (33) 6 (46) 2 (18) 0.21
 —daily dose of OCSa (mg), mean (range) 5.6 (1.0–15) 6.1 (1.0–15) 4.3 (2.5–6) 0.74
comorbidities
 —ECRS, n (%) 20 (83) 10 (77) 10 (91) 0.60
 —EOM, n (%) 11 (46) 3 (23) 8 (73) 0.038
 —AERD, n (%) 7 (29) 6 (46) 1 (10) 0.08
 —EGPA, n (%) 4 (17) 1 (8) 3 (27)b 0.30
 —atopic dermatitis, n (%) 1 (4) 1 (8) 0 (0) > 0.99
previous biologics
 —omalizumab, n (%) / median (range) (month) 5 (21) / 11 (3–88) 1 (8) / 3 (3) 4 (40) / 15.5 (4–88) 0.14 / 0.16
 —mepolizumab, n (%) / median (range) (month) 11 (46) / 21 (5–35) 11 (100) / 21 (5–35)
 —dupilumab, n (%) / median (range) (month) 1 (4) / 6 (6) 1 (8) / 6 (6)
number of benralizumab injections, median (range) 8 (2–11) 8 (2–10) 7 (4–11) 0.98
observation period (months), median (range) 11.5 (4–17) 11 (4–16) 14 (4–17) 0.79
  1. Data are presented as n (%) or mean (standard deviation), unless otherwise stated
  2. Abbreviations: SD standard deviation, ICS inhaled corticosteroid, LABA long-acting β-2 agonist, LAMA long-acting muscarinic antagonist, LTRA leukotriene receptor antagonist, OCS oral corticosteroids, ECRS eosinophilic chronic rhinosinusitis, EOM eosinophilic otitis media, AERD aspirin-exacerbated respiratory disease, EGPA eosinophilic granulomatosis with polyangiitis
  3. Fisher’s exact test, Mann-Whitney U test,
  4. aprednisone equivalents dose
  5. bAll three patients with EGPA received 100 mg of mepolizumab injection